Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Debt: 2015-2017

Historic Non-Current Debt for Lineage Cell Therapeutics (LCTX) over the last 2 years, with Dec 2017 value amounting to $18,000.

  • Lineage Cell Therapeutics' Non-Current Debt fell 85.00% to $18,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $18,000, marking a year-over-year decrease of 85.00%. This contributed to the annual value of $18,000 for FY2017, which is 85.00% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Non-Current Debt of $18,000 as of Q4 2017, which was down 59.09% from $44,000 recorded in Q3 2017.
  • Lineage Cell Therapeutics' Non-Current Debt's 5-year high stood at $268,000 during Q3 2015, with a 5-year trough of $18,000 in Q4 2017.
  • Moreover, its 3-year median value for Non-Current Debt was $146,500 (2016), whereas its average is $142,600.
  • Data for Lineage Cell Therapeutics' Non-Current Debt shows a maximum YoY tumbled of 85.00% (in 2017) over the last 5 years.
  • Quarterly analysis of 3 years shows Lineage Cell Therapeutics' Non-Current Debt stood at $220,000 in 2015, then plummeted by 45.45% to $120,000 in 2016, then plummeted by 85.00% to $18,000 in 2017.
  • Its Non-Current Debt stands at $18,000 for Q4 2017, versus $44,000 for Q3 2017 and $95,000 for Q2 2017.